Trust's refusal to fund trastuzumab was “arbitrary”
BMJ 2006; 332 doi: https://doi.org/10.1136/bmj.332.7544.747 (Published 30 March 2006) Cite this as: BMJ 2006;332:747- Clare Dyer, legal correspondent
- BMJ
An NHS trust that refused to pay for a woman with breast cancer to be treated with the monoclonal antibody trastuzumab (Herceptin) was accused of decision making that was “arbitrary in the extreme,” in the Court of Appeal this week.
David Pannick QC, counsel for Ann Marie Rogers, made the accusation as he launched an appeal against a High Court ruling last month upholding the stand taken by Swindon Primary Care Trust.
Ms Rogers, a 54 year old mother of three with HER2 breast cancer, has likened the trust's refusal to fund the £22 000 (€32 000; …
Log in
Log in using your username and password
Log in through your institution
Subscribe from £173 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£38 / $45 / €42 (excludes VAT)
You can download a PDF version for your personal record.